NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
종목 코드 NURO
회사 이름NeuroMetrix Inc
상장일Jul 22, 2004
CEODr. Shai N. Gozani, M.D., Ph.D.
직원 수13
유형Ordinary Share
회계 연도 종료Jul 22
주소1000 Winter Street
도시WALTHAM
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호02451
전화17818909989
웹사이트https://www.neurometrix.com/
종목 코드 NURO
상장일Jul 22, 2004
CEODr. Shai N. Gozani, M.D., Ph.D.
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음